Study guide
4.2 Gastrointestinal & Hepatorenal Disorders
Clinical Officers Council Pre-Internship Examination Kenya
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview & Exam Strategy
1.1 About the COC Pre-Internship Examination 1.2 Clinical Decision-Making & Preparation Strategy
2 Chapter 2: Infectious & Communicable Diseases (Internal Medicine)
2.1 Malaria Diagnosis & Case Management 2.2 Tuberculosis & Leprosy Control 2.3 HIV/AIDS & Opportunistic Infections 2.4 Enteric & Neglected Tropical Infections
3 Chapter 3: Cardiovascular & Respiratory Medicine (Internal Medicine)
3.1 Hypertension & Cardiovascular Disorders 3.2 Respiratory Disorders & Acute Emergencies 3.3 Venous Thromboembolism & Vascular Emergencies
4 Chapter 4: Metabolic, Gastrointestinal & Neurological Medicine (Internal Medicine)
4.1 Diabetes Mellitus & Endocrine Emergencies 4.2 Gastrointestinal & Hepatorenal Disorders 4.3 Neurological Emergencies & Acute Toxicology
5 Chapter 5: Trauma Resuscitation & Emergency Surgery (General Surgery)
5.1 ATLS Primary Survey & Trauma Resuscitation 5.2 Burn Assessment & Fluid Resuscitation 5.3 Surgical Wounds, Infections & Tetanus Prophylaxis
6 Chapter 6: Acute Abdomen & Gastrointestinal Surgery (General Surgery)
6.1 Acute Appendicitis & Peritonitis 6.2 Intestinal Obstruction & Abdominal Hernias 6.3 Hepatobiliary, Pancreatic & Anorectal Surgical Conditions
7 Chapter 7: Orthopedics, Urology & Special Surgical Emergencies (General Surgery)
7.1 Fractures, Dislocations & Cast Management 7.2 Acute Compartment Syndrome & Limb Emergencies 7.3 Urological Emergencies & Pelvic Trauma 7.4 Emergency Airway, Anesthesia & Oncology Screening
8 Chapter 8: Essential Newborn Care & Neonatal Conditions (Pediatrics)
8.1 Immediate Newborn Care & Neonatal Resuscitation 8.2 Neonatal Jaundice, Sepsis & Common Disorders 8.3 Low Birth Weight & Kangaroo Mother Care
9 Chapter 9: IMCI Guidelines & Common Pediatric Conditions (Pediatrics)
9.1 IMCI Principles & General Danger Signs 9.2 Cough, Fast Breathing & Pediatric Pneumonia 9.3 Pediatric Diarrheal Diseases & Dehydration 9.4 Acute Pediatric Infections: Meningitis, Croup & Febrile Seizures
10 Chapter 10: Child Nutrition, KEPI & Preventive Pediatrics (Pediatrics)
10.1 Severe Acute Malnutrition (SAM) Management 10.2 KEPI Immunization Schedule & Vaccine Logistics 10.3 Pediatric Prophylaxis & Early Infant Diagnosis
11 Chapter 11: Antenatal Care & Medical Complications of Pregnancy (Obstetrics & Gynecology)
11.1 Focused Antenatal Care & Routine ANC Screening 11.2 Hypertensive Disorders of Pregnancy & Eclampsia 11.3 Medical Disorders & Infections in Pregnancy
12 Chapter 12: Labor, Delivery & Obstetric Emergencies (Obstetrics & Gynecology)
12.1 Normal Labor & Partograph Monitoring 12.2 Active Management of the Third Stage of Labor & PPH 12.3 Antepartum Hemorrhage & Uterine Rupture 12.4 Induction of Labor & Malpresentation Emergencies
13 Chapter 13: Puerperium, Gynecological Disorders & Family Planning (Obstetrics & Gynecology)
13.1 Puerperal Sepsis & Postnatal Complications 13.2 Pelvic Inflammatory Disease & Gynecological Conditions 13.3 Modern Contraceptive Technology & WHO MEC Criteria
14 Chapter 14: Primary Health Care & Devolved Health Systems (Community Health)
14.1 Primary Health Care Principles & Universal Health Coverage 14.2 Kenya Health Service Delivery Structure & Devolved Governance 14.3 Kenya Community Health Strategy & Level 1 Services
15 Chapter 15: Epidemiology, Disease Surveillance & Outbreak Response (Community Health)
15.1 Epidemiological Principles & Health Indicators 15.2 Integrated Disease Surveillance and Response (IDSR) 15.3 Vector Control & Neglected Tropical Diseases
16 Chapter 16: Environmental Health, Waste Management & Cold Chain (Community Health)
16.1 Water Quality & Household Water Treatment 16.2 Community Sanitation & Excreta Disposal 16.3 Healthcare Waste Management & Infection Prevention Control 16.4 Vaccine Cold Chain Management & Quality Monitoring
17 Chapter 17: Health Systems Management — Leadership, Policy & Financing
17.1 Management Functions, Leadership & Supportive Supervision 17.2 Kenya Health Policy, Planning & the Devolved Budget Cycle 17.3 Health Financing & Universal Health Coverage under the Social Health Authority 17.4 Human Resource Management, Scheme of Service & Performance Appraisal
18 Chapter 18: Health Commodities, Information & Quality Management
18.1 Health Commodity & Supply Chain Management (KEMSA) 18.2 Health Information Systems, Records & KHIS Reporting 18.3 Quality Improvement, Clinical Audit & Patient Safety
19 Chapter 19: Professional Practice, Ethics & Medico-Legal Responsibility
19.1 Scope of Practice, Registration, Licensing & Professional Discipline 19.2 Medical Ethics, Informed Consent & Patient Rights 19.3 Medico-Legal Documentation, Statutory Notification & Facility Safety Governance
4.2 Gastrointestinal & Hepatorenal Disorders
Key Takeaways Explain This Topic AI
Peptic Ulcer Disease (PUD) manifests with distinct symptom chronobiology: duodenal ulcer pain typically occurs 2 to 3 hours postprandially or at night and improves with meals, whereas gastric ulcer pain is provoked or exacerbated by food intake; Helicobacter pylori eradication requires 14-day triple therapy comprising a high-dose PPI, Amoxicillin 1000 mg twice daily, and Clarithromycin 500 mg twice daily (or Metronidazole 400 mg twice daily in penicillin-allergic patients).
Acute Upper Gastrointestinal Bleeding mandates immediate resuscitation with large-bore IV access, restrictive blood transfusion targeting hemoglobin 7.0–8.0 g/dL, high-dose intravenous PPI (Omeprazole 80 mg bolus followed by 8 mg/hr infusion), vasoactive therapy (Terlipressin or Octreotide) for suspected varices, short-term prophylactic Ceftriaxone in cirrhotics, and diagnostic/therapeutic endoscopy within 24 hours.
Cirrhosis decompensation is evaluated using the Child-Pugh and MELD scores; uncomplicated ascites is treated with dietary sodium restriction (< 2 g/day) and dual diuretics combining Spironolactone and Furosemide in a fixed 100 mg : 40 mg ratio to preserve serum potassium balance.
Spontaneous Bacterial Peritonitis (SBP) is diagnosed by diagnostic paracentesis demonstrating an ascitic absolute neutrophil count >= 250 cells/mm3; management requires urgent empirical intravenous Ceftriaxone or Cefotaxime alongside intravenous albumin infusion (1.5 g/kg on day 1, 1.0 g/kg on day 3) to prevent hepatorenal syndrome and reduce mortality.
Acute Kidney Injury (AKI) is staged by KDIGO criteria (creatinine elevation >= 26.5 micromol/L in 48 hours or >= 1.5 times baseline, or oliguria < 0.5 mL/kg/hr for >= 6 hours); life-threatening hyperkalemia demands rapid myocardial stabilization with 10% IV Calcium Gluconate followed by intracellular potassium shifting using insulin-dextrose and nebulized salbutamol, with urgent hemodialysis indicated for refractory AEIOU complications.
Last updated: September 2026
4.2 Gastrointestinal & Hepatorenal Disorders
Core Clinical Rule: In acute upper gastrointestinal bleeding, adopt a restrictive blood transfusion threshold : transfuse packed red blood cells only when hemoglobin is < 7.0 g/dL < 7.0\text{ g/dL} < 7.0 g/dL to maintain a target of 7.0 to 8.0 g/dL (8.0 to 9.0 g/dL in severe cardiovascular disease). Overzealous, liberal transfusion increases portal venous pressure, dislodges fragile platelet-fibrin plugs, dramatically increases rebleeding rates, and escalates mortality. In decompensated cirrhotics presenting with upper GI bleeding, always administer prophylactic IV Ceftriaxone immediately to prevent Spontaneous Bacterial Peritonitis and death.
Gastrointestinal, hepatic, and renal disorders account for high rates of emergency department presentations and hospital morbidity across East Africa. Patients frequently present with hematemesis, jaundice, abdominal distension, or oliguria. Clinical officers must be adept at clinical risk stratification, procedural paracentesis, rational pharmacotherapy, and rapid intervention for life-threatening electrolyte disturbances.
1. Peptic Ulcer Disease (PUD) & Helicobacter pylori Eradication
Peptic Ulcer Disease results from a pathological imbalance between mucosal protective mechanisms (mucus-bicarbonate barrier, mucosal blood flow, prostaglandins, cellular restitution) and aggressive luminal factors (gastric acid, pepsin, Helicobacter pylori infection, and Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
Clinical Differentiation of Gastric vs Duodenal Ulcers
- Clinical Characteristic Duodenal Ulcer (DU) Gastric Ulcer (GU)
- Relative Frequency ~80% of all peptic ulcers ~20% of all peptic ulcers
- Typical Age of Onset 30 to 55 years (younger) 55 to 70 years (older)
- H. pylori Association > 90 % > 90\% > 90% of cases 70% to 80% of cases
- Acid Output Normal to markedly elevated Normal to low / hypochlorhydria
Pain Chronobiology Relieved by food intake or antacids; pain occurs 2 to 3 hours postprandially Worsened by food intake (provoked within 15–30 minutes of eating)
Nocturnal Awakening Common (wakes patient between 12:00 AM and 3:00 AM) Rare
Appetite & Weight Preserved or increased; patients may gain weight Anorexia, food avoidance; unintended weight loss common
Malignancy Risk Almost universally benign ( < 1 % < 1\% < 1% ) Up to 5% are malignant (gastric adenocarcinoma)
Endoscopic Mandate Routine repeat biopsy after healing not required Mandatory multiple biopsies at initial endoscopy and repeat endoscopy at 6–8 weeks to confirm complete healing
Helicobacter pylori Eradication Regimens (Kenya MOH / WHO Guidelines)
Helicobacter pylori is a microaerophilic, flagellated, gram-negative spiral bacterium that colonizes the gastric antrum and body. It produces copious urease, which hydrolyzes urea into carbon dioxide and ammonia, neutralizing gastric acid in its microenvironment and damaging mucosal epithelium. +-----------------------------------------------------------------------------------+
- | FIRST-LINE TRIPLE THERAPY REGIMEN (14 DAYS DURATION) |
- +-----------------------------------------------------------------------------------+
- | 1. Proton Pump Inhibitor (PPI): Omeprazole 20 mg PO twice daily |
- | (or Esomeprazole 20-40 mg PO twice daily, or Pantoprazole 40 mg PO twice daily)|
- | 2. Amoxicillin: 1000 mg (1 g) PO twice daily |
- | 3. Clarithromycin: 500 mg PO twice daily |
- +-----------------------------------------------------------------------------------+
- | PENICILLIN ALLERGY ALTERNATIVE: |
- | Replace Amoxicillin with Metronidazole 400 mg (or 500 mg) PO twice daily. |
- +-----------------------------------------------------------------------------------+
- | BISMUTH QUADRUPLE THERAPY (Second-Line / High Resistance Settings): |
- | PPI standard dose BID + Bismuth Subsalicylate 524 mg QID + Metronidazole 400 mg |
- | TID or QID + Tetracycline 500 mg QID for 14 days. |
- +-----------------------------------------------------------------------------------+
Testing for Eradication: To confirm bacterial clearance, perform a Stool Antigen Test or Urea Breath Test at least 4 weeks after completion of antibiotic therapy and at least 2 weeks after stopping PPI therapy . Serological antibody testing remains positive for months to years and must never be used to confirm cure.
2. Acute Upper Gastrointestinal Bleeding (UGIB)
Upper GI bleeding is defined as hemorrhage originating proximal to the ligament of Treitz (duodenojejunal junction). Common etiologies include bleeding peptic ulcer disease (50%), ruptured esophageal or gastric varices (15–20%), Mallory-Weiss tears, erosive gastritis/duodenitis, and upper gastrointestinal malignancies.
Clinical Presentation & Triage
Hematemesis: Vomiting of bright red blood or dark altered blood ('coffee-ground' emesis).
Melena: Passage of black, tarry, foul-smelling stools resulting from bacterial degradation of hemoglobin in the small intestine (requires >= 50–100 mL of blood).
Hematochezia: Passage of fresh maroon or red blood per rectum; typically indicates lower GI bleeding, but occurs in 10–15% of massive upper GI hemorrhages with hypermotile intestinal transit and hemodynamic collapse.
- Stepwise Emergency Resuscitation Protocol [Suspected Acute Upper GI Bleeding / Hematemesis]
- |
- +-----------------------------------+-----------------------------------+
- | |
- [AIRWAY & BREATHING] [CIRCULATION / RESUSCITATION]
- High-flow oxygen if SpO2 < 94% • TWO large-bore IVs (14G or 16G)
- Endotracheal intubation if: • Send immediate cross-match, FBC,
- Massive hematemesis U&E, LFTs, Coagulation (PT/INR)
- Altered consciousness (GCS < 8) • Infuse isotonic crystalloids
- Severe encephalopathy (Hartmann's or Normal Saline)
- | |
- +-----------------------------------+-----------------------------------+
- v
- [TRANSFUSION TARGET STRATEGY]
- Restrictive Strategy: Target Hb 7.0 - 8.0 g/dL
- Target Hb 8.0 - 9.0 g/dL ONLY if active acute CAD
- |
- +-----------------------------------+-----------------------------------+
- | |
- [NON-VARICEAL BLEEDING (PUD)] [VARICEAL BLEEDING (CIRRHOSIS)]
- IV High-Dose PPI: • Vasoactive Splanchnic Constrictor:
- Omeprazole 80 mg IV bolus, Terlipressin 2 mg IV q4h OR
- then 8 mg/hr continuous infusion x 72h Octreotide 50 mcg bolus, then 50 mcg/hr
(or 40 mg IV BID) • Prophylactic Antibiotic:
- Ceftriaxone 1 g IV daily x 5-7 days
- | |
- +-----------------------------------+-----------------------------------+
- v
- [URGENT DIAGNOSTIC & THERAPEUTIC ENDOSCOPY]
- Perform within 24 hours of presentation
- Variceal: Endoscopic Variceal Band Ligation (EVL)
- Non-Variceal: Dual therapy (Epinephrine + Clips/Cautery)
Rationale for High-Dose PPI: Gastric acid prevents platelet aggregation and dissolves fibrin clots. At a gastric p H > 6.0 pH > 6.0 p H > 6.0 , platelet aggregation is restored and clot stabilization occurs.
Vasoactive Agents: Terlipressin (a synthetic vasopressin analogue with longer half-life) or Octreotide (a somatostatin analogue) cause selective splanchnic arterial vasoconstriction, significantly reducing portal venous blood flow, portal venous pressure, and variceal hemorrhage.
Bacterial Prophylaxis in Cirrhotics: Cirrhotic patients with GI hemorrhage have up to a 50% incidence of severe bacterial infections (SBP, bacteremia, pneumonia) within 7 days. Administering IV Ceftriaxone 1 g daily for 5 to 7 days reduces recurrent bleeding, infections, and all-cause mortality.
3. Chronic Liver Disease & Cirrhosis Decompensation
Cirrhosis is the histopathological end-stage of chronic progressive liver injury characterized by diffuse parenchymal destruction, regenerative nodule formation, and extensive fibrous bridging. Common causes in Kenya include chronic Hepatitis B virus (HBV), Hepatitis C virus (HCV), chronic alcohol use, Non-Alcoholic Fatty Liver Disease (MASLD), and Schistosoma mansoni (causing portal hypertension via periportal Symmers' pipestem fibrosis).
Child-Turcotte-Pugh (CTP) Prognostic Score
Evaluates 5 clinical and biochemical parameters (1 to 3 points each):
Parameter 1 Point 2 Points 3 Points
Total Bilirubin (micromol/L) < 34 < 34 < 34 ( < 2.0 mg/dL < 2.0\text{ mg/dL} < 2.0 mg/dL ) 34 − 50 34 - 50 34 − 50 ( 2.0 − 3.0 mg/dL 2.0 - 3.0\text{ mg/dL} 2.0 − 3.0 mg/dL ) > 50 > 50 > 50 ( > 3.0 mg/dL > 3.0\text{ mg/dL} > 3.0 mg/dL )
Serum Albumin (g/L) > 35 > 35 > 35 ( > 3.5 g/dL > 3.5\text{ g/dL} > 3.5 g/dL ) 28 − 35 28 - 35 28 − 35 ( 2.8 − 3.5 g/dL 2.8 - 3.5\text{ g/dL} 2.8 − 3.5 g/dL ) < 28 < 28 < 28 ( < 2.8 g/dL < 2.8\text{ g/dL} < 2.8 g/dL )
INR / Prothrombin Time (sec) < 1.7 < 1.7 < 1.7 ( < 4 s prolonged < 4\text{ s prolonged} < 4 s prolonged ) 1.7 − 2.3 1.7 - 2.3 1.7 − 2.3 ( 4 − 6 s prolonged 4 - 6\text{ s prolonged} 4 − 6 s prolonged ) > 2.3 > 2.3 > 2.3 ( > 6 s prolonged > 6\text{ s prolonged} > 6 s prolonged )
- Ascites None Mild / Moderate (medically controlled) Severe / Refractory / Tense
- Hepatic Encephalopathy None Grade 1 to 2 Grade 3 to 4
Class Interpretation: Class A (5–6 points: well-compensated, 1-year survival 100%); Class B (7–9 points: significant functional compromise, 1-year survival 80%); Class C (10–15 points: decompensated end-stage, 1-year survival 45%).
Ascites Evaluation & Serum-Ascites Albumin Gradient (SAAG)
Ascites is the pathological accumulation of free fluid within the peritoneal cavity. Diagnostic paracentesis is mandatory for all patients with new-onset ascites or hospital admission for worsening ascites.
SAAG Calculation: SAAG = Serum Albumin (g/L) − Ascitic Fluid Albumin (g/L) \text{SAAG} = \text{Serum Albumin (g/L)} - \text{Ascitic Fluid Albumin (g/L)} SAAG = Serum Albumin (g/L) − Ascitic Fluid Albumin (g/L)
High SAAG ( ≥ 11 g/L \ge 11\text{ g/L} ≥ 11 g/L or ≥ 1.1 g/dL \ge 1.1\text{ g/dL} ≥ 1.1 g/dL ): Indicates Portal Hypertension (sinusoidal hypertension creates hydrostatic transudation). Causes: Cirrhosis, alcoholic hepatitis, congestive heart failure, Budd-Chiari syndrome, constrictive pericarditis.
Low SAAG ( < 11 g/L < 11\text{ g/L} < 11 g/L or < 1.1 g/dL < 1.1\text{ g/dL} < 1.1 g/dL ): Indicates Non-Portal Etiology (increased peritoneal capillary permeability or lymphatic blockage). Causes: Peritoneal carcinomatosis, peritoneal tuberculosis, nephrotic syndrome, acute pancreatitis, bowel obstruction.
Pharmacological Management:
Dietary sodium restriction to < 2.0 g/day < 2.0\text{ g/day} < 2.0 g/day (88 mmol/day).
Dual Diuretic Therapy: Combine Spironolactone (aldosterone antagonist) and Furosemide (loop diuretic) in a fixed 100 mg : 40 mg ratio (e.g., Spironolactone 100 mg + Furosemide 40 mg PO daily; titrated every 3–5 days up to a maximum of 400 mg : 160 mg). This ratio maintains normokalemia and targets weight loss of 0.5 kg/day (or 1.0 kg/day if concurrent peripheral edema).
Refractory Ascites: Perform Large-Volume Paracentesis (LVP) . When removing > 5 Liters > 5\text{ Liters} > 5 Liters of ascitic fluid, infuse intravenous Albumin (20% or 25% solution) at a dose of 6 to 8 grams per liter of ascitic fluid removed to prevent Paracentesis-Induced Circulatory Dysfunction (PICD), rapid renal failure, and death.
Spontaneous Bacterial Peritonitis (SBP)
SBP is an acute bacterial infection of ascitic fluid occurring in the absence of an identifiable surgically remediable intra-abdominal source. Driven by bacterial translocation across permeable gut walls into mesenteric lymph nodes and ascitic fluid.
Diagnostic Criterion: Diagnostic paracentesis revealing an ascitic fluid absolute neutrophil count (ANC) ≥ 250 cells/mm 3 \ge 250\text{ cells/mm}^3 ≥ 250 cells/mm 3 (calculated as Total Ascitic WBC × % Polymorphonuclear cells \text{Total Ascitic WBC} \times \%\text{ Polymorphonuclear cells} Total Ascitic WBC × % Polymorphonuclear cells ). Common pathogens: Escherichia coli , Klebsiella pneumoniae , and Streptococcus pneumoniae .
Therapeutic Regimen:
Empirical Antibiotics: IV Ceftriaxone 2 g once daily OR IV Cefotaxime 2 g 8-hourly for 5 to 7 days.
Intravenous Albumin (Mandatory Survival Intervention): Administer Albumin 1.5 g/kg IV within 6 hours of diagnosis , followed by 1.0 g/kg IV on Day 3 . This reduces the incidence of hepatorenal syndrome from 30% to 10% and cuts hospital mortality from 29% to 10%.
Secondary Prophylaxis: After completing therapy, initiate lifelong oral Ciprofloxacin 500 mg daily or Norfloxacin 400 mg daily to prevent recurrent SBP.
Hepatic Encephalopathy (HE)
A spectrum of reversible neuropsychiatric abnormalities resulting from portal-systemic shunting and hepatocellular failure, allowing neurotoxic gut products (primarily ammonia, N H 3 NH_3 N H 3 ) to bypass hepatic clearance and enter the systemic and cerebral circulations.
West Haven Staging Criteria:
Grade 1: Trivial lack of awareness, shortened attention span, euphoria or anxiety, reversed sleep-wake cycle.
Grade 2: Lethargy, apathy, disinhibited behavior, slurred speech, overt asterixis ('flapping tremor') .
Grade 3: Somnolence to semi-stupor, responsive to verbal stimuli, marked confusion, gross disorientation.
Grade 4: Coma (unresponsive to verbal or painful stimuli).
Identify & Treat Precipitating Causes: Gastrointestinal bleeding (nitrogen load), infection (SBP, UTI, pneumonia), constipation, hypokalemic metabolic alkalosis (promotes conversion of unabsorbable ammonium N H 4 + NH_4^+ N H 4 + to diffusible N H 3 NH_3 N H 3 ), overdiuresis, dehydration, or sedatives.
Medical Therapy:
Lactulose (First-Line): 20 to 30 mL (15–30 g) orally or via nasogastric tube 2 to 4 times daily, titrated to achieve 2 to 3 soft, semiformed bowel movements per day . Lactulose is degraded by colonic flora into lactic and acetic acids, acidifying the colon lumen ( p H < 5.0 pH < 5.0 p H < 5.0 ), converting ammonia ( N H 3 NH_3 N H 3 ) to unabsorbable ammonium ( N H 4 + NH_4^+ N H 4 + ), trapping it for excretion, and exerting an osmotic laxative effect.
Rifaximin: 550 mg PO twice daily added to lactulose for secondary prevention of recurrent encephalopathy; reduces ammonia-producing colonic bacteria without systemic absorption.
4. Acute Kidney Injury (AKI) & Life-Threatening Hyperkalemia
Acute Kidney Injury is defined as an abrupt reduction in kidney function resulting in retention of nitrogenous waste products (urea, creatinine) and dysregulation of extracellular fluid volume and electrolytes.
KDIGO Staging Criteria for AKI +-----------------------------------------------------------------------------------+
- | KDIGO CLINICAL STAGING FOR AKI |
- +-----------------------------------------------------------------------------------+
- | Stage | Serum Creatinine Criteria | Urine Output Criteria |
- +-------+---------------------------------------------+-----------------------------+
- | 1 | Rise >= 26.5 micromol/L (>= 0.3 mg/dL) in 48h| < 0.5 mL/kg/hr for 6-12 |
- | | OR 1.5 to 1.9 times baseline within 7 days | consecutive hours |
- +-------+---------------------------------------------+-----------------------------+
- | 2 | 2.0 to 2.9 times baseline | < 0.5 mL/kg/hr for >= 12 |
- | | | consecutive hours |
- +-------+---------------------------------------------+-----------------------------+
- | 3 | >= 3.0 times baseline | < 0.3 mL/kg/hr for >= 24h |
- | | OR Serum Creatinine >= 353.6 micromol/L | OR Anuria for >= 12 hours |
- | | OR Initiation of Renal Replacement Therapy | |
- +-----------------------------------------------------------------------------------+
- Etiological Classification: Prerenal vs Intrinsic vs Postrenal
Parameter Prerenal Azotemia Intrinsic Renal (Acute Tubular Necrosis - ATN) Postrenal (Obstruction)
Mechanism Renal hypoperfusion (dehydration, sepsis, heart failure) Direct parenchymal tubular or interstitial injury Physical outflow obstruction (BPH, cervical ca, stones)
BUN / Serum Creatinine Ratio > 20 : 1 > 20 : 1 > 20 : 1 (high reabsorption of urea) < 15 : 1 < 15 : 1 < 15 : 1 (tubular reabsorption lost) Variable
Fractional Excretion of Sodium (FeNa) < 1.0 % < 1.0\% < 1.0% (kidneys avidly reabsorb sodium) > 2.0 % > 2.0\% > 2.0% (damaged tubules cannot reabsorb sodium) > 1.0 % > 1.0\% > 1.0% (early < 1 % < 1\% < 1% , late > 1 % > 1\% > 1% )
Urine Sodium Concentration < 20 mmol/L < 20\text{ mmol/L} < 20 mmol/L > 40 mmol/L > 40\text{ mmol/L} > 40 mmol/L > 40 mmol/L > 40\text{ mmol/L} > 40 mmol/L
Urine Specific Gravity / Osmolality Concentrated ( > 1.020 > 1.020 > 1.020 / > 500 mOsm/kg > 500\text{ mOsm/kg} > 500 mOsm/kg ) Isosthenuric ( 1.010 1.010 1.010 / < 350 mOsm/kg < 350\text{ mOsm/kg} < 350 mOsm/kg ) Variable
Urinary Microscopy Normal or Hyaline casts 'Muddy brown' granular casts , tubular epithelial cells Normal, RBCs, WBCs, or crystals
Emergency Management of Life-Threatening Hyperkalemia
Severe hyperkalemia is defined as a serum potassium > 6.5 mmol/L > 6.5\text{ mmol/L} > 6.5 mmol/L or any potassium elevation accompanied by electrocardiographic changes : tall tented peaked T waves → \rightarrow → prolonged PR interval → \rightarrow → flattening/loss of P wave → \rightarrow → widening of QRS complex → \rightarrow → 'sine wave' pattern → \rightarrow → ventricular fibrillation or asystole. +-----------------------------------------------------------------------------------+
- | STEPWISE EMERGENCY HYPERKALEMIA MANAGEMENT PROTOCOL |
- +-----------------------------------------------------------------------------------+
- | 1. CARDIOPROTECTION (IMMEDIATE) |
- | • 10% Calcium Gluconate: 10 mL IV slow push over 5 to 10 minutes. |
- | • Mechanism: Antagonizes potassium-induced membrane excitability; restores |
- | myocardial resting membrane potential. Does NOT lower serum K+ levels! |
- | • Onset: 1-3 minutes; duration 30-60 minutes. Repeat in 5-10 min if ECG persists|
- +-----------------------------------------------------------------------------------+
- | 2. INTRACELLULAR POTASSIUM SHIFTING (FAST REDISTRIBUTION) |
- | • Regular Insulin + Dextrose: 10 units Regular Insulin in 50 mL 50% Dextrose |
- | (or 100 mL 20% Dextrose) infused IV over 20 to 30 minutes. |
- | (Stimulates Na+/K+-ATPase; lowers K+ by 0.5-1.0 mmol/L within 30-60 min). |
- | • Nebulized Salbutamol: 10 to 20 mg nebulized in 4 mL normal saline over 15 min|
- | (Synergistic beta-2 receptor mediated intracellular potassium uptake). |
- | • Sodium Bicarbonate: 50-100 mEq IV infusion ONLY if severe concurrent acidosis|
- +-----------------------------------------------------------------------------------+
- | 3. POTASSIUM ELIMINATION FROM THE BODY (DEFINITIVE CLEARANCE) |
- | • Loop Diuretic: IV Furosemide 40-80 mg (if residual renal perfusion exists). |
- | • Gastrointestinal K+ Binders: Calcium Polystyrene Sulfonate (Calcium Resonium)|
- | 15 g PO 8-hourly, or Sodium Zirconium Cyclosilicate (Lokelma). |
- +-----------------------------------------------------------------------------------+
- | 4. EMERGENCY HEMODIALYSIS (REFRACTORY CASES) |
- | • Definitive clearance modality for severe refractory hyperkalemia. |
- +-----------------------------------------------------------------------------------+
- Indications for Emergency Hemodialysis: The 'AEIOU' Mnemonic
A - Acidosis: Severe, uncorrectable metabolic acidosis ( p H < 7.15 pH < 7.15 p H < 7.15 or refractory to medical therapy).
E - Electrolytes: Severe, refractory hyperkalemia ( K + > 6.5 mmol/L K^+ > 6.5\text{ mmol/L} K + > 6.5 mmol/L ) or rapid worsening despite medical shifting.
I - Ingestions / Toxins: Dialyzable toxic ingestions: SLIME ( S alicylates, L ithium, I sopropanol, M ethanol, E thylene glycol).
O - Overload: Intractable hypervolemic pulmonary edema refractory to high-dose loop diuretics.
U - Uremia: Symptomatic uremic end-organ complications: uremic pericarditis (pericardial friction rub), uremic encephalopathy (confusion, asterixis, seizures, coma), or uremic coagulopathy (abnormal platelet function and bleeding).